X線基準を満たさない体軸型関節炎患者におけるセクキヌマブのフェーズ3無作為化試験からの2年間の画像結果
Arthritis Res Ther. 2023;16;25(1):80 doi 10.1186/s13075-023-03051-5
Braun et al. studied a large cohort of patients with nr-axSpA, that demonstrated a secukinumab reduced SI joint inflammation (BME), this reduction was sustained over 104 weeks, from an overall low baseline level of spinal inflammation or structural damage.
In this paper a randomised, double-blind, placebo controlled, multicentre phase 3 study was conducted, evaluable patients were assessed, and a greater reduction was seen in patients with definite SI joint inflammation at baseline.
Keywords:
